A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled 52 Weeks Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o.(300-1200 mg/Day) as Adjuvant Therapy in the Bipolar Disorder I or II Treatment.

Trial Profile

A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled 52 Weeks Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o.(300-1200 mg/Day) as Adjuvant Therapy in the Bipolar Disorder I or II Treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Oxcarbazepine (Primary)
  • Indications Bipolar I disorders; Bipolar II disorders
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Jun 2008 Primary endpoint 'Time to disease recurrence' has not been met.
    • 01 Jun 2008 Secondary endpoint 'Global Assessment of Functioning' has not been met.
    • 01 Jun 2008 Primary endpoint 'Montgomery Asberg Depression Rating Scale' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top